DCAT Week 2025, the premier gathering of global leaders in the biopharmaceutical industry, welcomed Sinopep’s leadership delegation, headed by Mr. Tong Ziquan (Chairman) and Mr. Li Xiaohua (Senior Vice President), together with the Business Development team.
During the event, Sinopep engaged in productive discussions with global partners and customers, reinforcing existing collaborations and exploring new opportunities for strategic growth.
The company’s participation followed a significant milestone achieved in September 2024, when Sinopep successfully passed the U.S. FDA’s unannounced cGMP inspection. This achievement was a strong testament to the company’s commitment to operational excellence and earned broad recognition from customers for its high-quality standards.
Sinopep remains steadfast in advancing its platform-based strategy and upholding the highest levels of professionalism, delivering long-term value to customers, partners, and society at large.
